Breast Cancer Clinical Trials in Detroit

Showing 201-220 of 706 trials

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

NCT03589339

The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.

RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant Tumour+8 more

Nanobiotix145 participantsStarted Jan 2019

San Francisco, California, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +10 more locations

RECRUITINGPhase 1< 1 mile

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

NCT05508906

This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: Palazestrant (OP-1250) in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: Palazestrant (OP-1250) in combination with everolimus. Treatment Group 4: Palazestrant (OP-1250) in combination with atirmociclib.

Metastatic Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+2 more

Olema Pharmaceuticals, Inc.190 participantsStarted Aug 2022

Gilbert, Arizona, United States • San Francisco, California, United States • Aurora, Colorado, United States +13 more locations

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Breast Cancer Trials in Other Cities

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

Other Conditions in Detroit